ArticleScientific reports2026
BactProNET: a structural-mechanistic platform for interpreting target-mediated antimicrobial resistance.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Antibiotics are the frontline therapy for bacterial infections, yet their efficacy is critically threatened by antimicrobial resistance (AMR), a crisis largely driven by mutations in protein targets. While this mechanism is prevalent, data on its structural impact remains highly dispersed, and existing resources such as CARD, ResFinder, MEGARes, and NDARO prioritize gene identification over mechanistic insight. To address this gap, we developed BactProNET, a bioinformatics platform focused specifically on target-mediated resistance caused by amino acid substitutions in antibiotic target proteins. It provides structural and evolutionary analysis distinct from broader AMR databases. Its core innovation is a multi-level data integration that establishes a wild-type reference system and enables comparative analysis with mutant proteins to facilitate mechanistic inference. The platform integrates curated resistance mutations with AlphaFold2-predicted three-dimensional (3D) structures, both wild-type and mutant molecular docking models defining an "optimal binding" baseline and its potential disruption by resistance mutations, and integrated phylogenetic and sequence alignment views. BactProNET currently houses data on 44 bacterial species, 107 protein targets, 196 mutation sites (representing 243 unique amino acid substitutions), 323 antibiotics, and 640 wild-type plus 1,697 mutant docking models. The platform is accessible via an interface with embedded basic local alignment search tool (BLAST) and multiple sequence alignment (MSA) tools. As a one-stop platform for target-mediated resistance, it facilitates the interpretation of AMR's molecular mechanisms and provides a data-driven foundation for the rational design of next-generation antimicrobial drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.